✦ LIBER ✦

Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder

✍ Scribed by Jeffrey E. Kelsey

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 83 KB
Volume: 12
Category: Article
ISSN: 1091-4269
DOI: 10.1002/1520-6394(2000)12:1+<81::aid-da11>3.0.co;2-f

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of ondansetron in the treatment

Efficacy of ondansetron in the treatment of generalized anxiety disorder

✍ A. M. Freeman III; J. R. Westphal; G. T. Norris; B. A. Roggero; P. B. Webb; K. L 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

Ondansetron is a highly selective antagonist at the 5-HT 3 subtype of serotonin (5-HT) receptors . The 5-HT 3 receptors are the only receptors whose effects are mediated through the ion channels rather than the G-protein series . Ondansetron has no appreciable affinity for other 5-HT receptor subtyp

Efficacy of venlafaxine in mixed depress

Efficacy of venlafaxine in mixed depression-anxiety states

✍ Jack M. Gorman; Laszlo A. Papp 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB 👁 1 views

Comparing primary and secondary generali

Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders

✍ Malcolm P. Rogers; Meredith G. Warshaw; Robert M. Goisman; Idell Goldenberg; Fer 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

This study explores the potential differences in comorbidity and course between primary generalized anxiety disorder (GAD), which develops before other anxiety disorders, and secondary GAD. As part of the Harvard/Brown Anxiety Research Project (HARP), a naturalistic, long-term, longitudinal study of

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety

✍ M. Linden; D. Hadler; S. Hofmann 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Generalized anxiety disorders are frequent, chronic, and disabling illnesses for which so far ideal drug treatment is not available. A new promising anxiolytic drug is DN-2327, a non-benzodiazepine isoindoline derivative, which has shown in animals to have anxiolytic, taming, antiaggressive, and ant

Meta-analysis of the safety and tolerabi

Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety

✍ John J. Sramek; Walter W. Hong; Suha Hamid; Barbara Nape; Neal R. Cutler 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Buspirone is an azapirone with 5-HT 1A partial agonist activity which has demonstrated efficacy in the treatment of generalized anxiety disorder, commonly referred to as persistent anxiety. In this meta-analysis report, safety results from two studies comparing buspirone 15 mg twice daily (BID) with

The role of positive beliefs about worry

The role of positive beliefs about worry in generalized anxiety disorder and its treatment

✍ T. D. Borkovec; H. Hazlett-Stevens; M. L. Diaz 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Individuals suffering from generalized anxiety disorder hold a variety of beliefs about the possible benefits of their worrying. The present article suggests that these beliefs emerge from both short-term and long-term experiences with negative reinforcement of the worry process. Elements of treatme